A Phase 1/2 interventional study of IBI362 and Placebo in Overweight or Obesity, sponsored by Innovent Biologics (Suzhou) Co. Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-11-28.
Sponsored by Innovent Biologics (Suzhou) Co. Ltd. (part of Innovent Biologics, Inc.) · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies testing mazdutide in Obesity — 11 open to participants now, 14 under way, 4 of them phase 3. mazdutide · Obesity.
Among the 22 studies testing mazdutide in Obesity, this one is the 18th largest by enrollment, is the only one that started in 2020, is one of 2 in phase 1/2, and was the 1st registered.
11,543 studies on the registry are indexed under Obesity; 2,042 are open to participants now.
Browse Obesity studies →11 of the 22 studies testing mazdutide in Obesity are open now, in 3 countries. Recruiting first, the newest first:
China National Center for Cardiovascular Diseases · Sites in China
Ages 18+
Shanghai Zhongshan Hospital · Sites in China
Ages 18+
China-Japan Friendship Hospital · Sites in China
Ages 18–60
Innovent Biologics (Suzhou) Co. Ltd. · Sites in China
Ages 18+
Innovent Biologics (Suzhou) Co. Ltd. · Sites in China
Ages 12–18
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 1,339 Obesity studies recruiting now, 377 (28%) set no upper age limit and 859 (64%) stop at 75 or younger; 167 take children under 18; 490 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, mazdutide is the treatment under test here. Read study by study →
22 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 7 · Phase 3 6 · Phase 4 2
First in 2020; this study’s year is marked. 1 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 60 is below the median of 67 across 9,016 interventional studies indexed under Obesity.
Median enrollment 187 across the 22 interventional studies. Of the 8 that completed or were terminated, 1 (13%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 22 have an industry lead sponsor. The 8 most frequent:
This study is registered under Innovent Biologics (Suzhou) Co. Ltd., one of the names counted as Innovent Biologics, Inc.. Under that name alone:
Innovent Biologics (Suzhou) Co. Ltd. is the lead sponsor of 199 studies on the registry; 46 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 1 (20%) have results posted.
16 studies in Obesity by Innovent Biologics, Inc.: 5 open now, 9 under way, 4 of them phase 3. Of 7 finished, 0 (0%) have results posted.
Among the 16 studies in Obesity by Innovent Biologics, Inc., this one is the 14th largest by enrollment, is the only one that started in 2020, is one of 2 in phase 1/2, and was the 1st registered.
Innovent Biologics, Inc.’s Obesity studies by the year they started, since 2020.
3 of the studies testing mazdutide in Obesity that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06931028Phase 3Innovent Biologics (Suzhou) Co. Ltd.A Study of IBI362 in Chinese Subjects With Obstructive Sleep Apnea and BMI≥28 kg/m2 | 2027-05-07 |
| NCT07255209Phase 3Innovent Biologics (Suzhou) Co. Ltd.A Study of IBI362 in Chinese Adolescents With Obesity or Overweight | 2027-10-31 |
| NCT06143956Eli Lilly and CompanyA Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight | 2027-09 |
Add all 3 to your calendar (.ics) → With an account.
Among the 22 studies testing mazdutide in Obesity, from their registry updates:
Among Innovent Biologics, Inc.’s 16 in Obesity:
This tab as a report to print or save as PDF → With an account.
This trial is conducted in China. The aim of this trial is to investigate Safety, Tolerability, PK and PD for Multiple Doses of IBI362 in Overweight or Obese Male and Female Subjects.
11,543 studies on the registry are indexed under Obesity; 2,042 are open to participants now.
This study's enrollment of 60 is below the median of 67 across 9,016 interventional studies indexed under Obesity.
Browse Obesity studies →Innovent Biologics (Suzhou) Co. Ltd. is the lead sponsor of 199 studies on the registry; 46 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 1 (20%) have results posted.
Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Overweight. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received dose 1 level of IBI362 administered as multiple subcutaneous doses. Participants received dose 2 level of IBI362 administered as multiple subcutaneous doses. Participants received dose 3 level of IBI362 administered as multiple subcutaneous doses. Participants received dose 4 level of IBI362 administered as multiple subcutaneous doses. Participants received dose 5 level of IBI362 administered as multiple subcutaneous doses.
Drug: IBI362
Participants received matching placebo dose regiments by subcutaneous injection
Drug: Placebo
Administered by subcutaneous injection
Administered by subcutaneous injection
Number of treatment adverse events
The relationship of each adverse event to the investigational product was assessed by the investigator.
Time frame: From the time of first dosing (Day 1 ) until completion of the post treatment follow-up visit (20 week)
Number of Participants With Anti-IBI362 Antibodies
Serum samples were analyzed by an electrochemiluminescence (ECL)-based immunoassay for anti-IBI362 binding antibodies. Positive samples were subsequently tested in a receptor-ligand binding bioassay for anti-IBI362 neutralizing antibodies.
Time frame: From the time of first dosing (Day 1 )until comletion of the post treatment follow-up visit (20 week)
Evaluate the Peak Plasma Concentration (Cmax) of IBI362 in overweight or obesity subjects;
Time frame: From the first dose (Day 1 ) of study drug until 12 week
Evaluate the Area under the plasma concentration versus time curve (AUC) of IBI362 in overweight or obesity subjects;
Time frame: From the first dose (Day 1 ) of study drug until 12 week
Evaluate the Fasting Blood Glucose (FBG ) of IBI362 in overweight or obesity subjects;
Time frame: From the first dose (Day 1 ) of study drug until 12 week
Evaluate the Glucagon of IBI362 in overweight or obesity subjects;
Time frame: From the first dose (Day 1 ) of study drug until 12 week
Evaluate the Insulin of IBI362 in overweight or obesity subjects;
Time frame: From the first dose (Day 1 ) of study drug until 12 week
Evaluate the C-peptide of IBI362 in overweight or obesity subjects;
Time frame: From the first dose (Day 1 ) of study drug until 12 week
Change in body weight from baseline
Time frame: Baseline (Day 1 ) and 12 week for groups
Ran from Jun 2020 to primary completion in Jun 2021, 12 months.
Of 62 phase 1/2 interventional studies under Obesity, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 36. This study's 12 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Mazdutide
Innovent Biologics (Suzhou) Co. Ltd. →